Name: PLX Income Statement - Protalix Biotherapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

PLX - Protalix Biotherapeutics, Inc.

USD | NYSE | Healthcare

PLX Income Statement - Protalix Biotherapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	33.8	9.1	17.9	15.7	10.1	18.2	18.0	13.5	3.7	10.5	10.3	35.1	9.6	8.6	14.2	8.8

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenues
Revenues	76.4	52.7	53.4	65.5	47.6	38.4	62.9	54.7	34.2	21.1	9.2	4.4	3.5	0.0	34.9	8.4	6.6	0.4
Cost of Revenue	22.9	27.0	24.3	23.0	19.6	16.3	10.9	10.9	9.3	15.2	8.4	0.7	0.6	0.0	8.1	1.5	4.4	3.6
Gross Profit	53.4	25.8	29.1	42.5	28.0	22.0	52.0	43.8	24.9	5.8	0.8	3.6	2.9	0.0	26.7	6.9	2.3
Operating Expenses
Research & Development	21.5	19.6	13.0	17.1	29.3	29.7	38.2	44.6	33.3	32.2	30.4	24.9	27.4	29.2	36.7
Operating Income
Operating Income	19.8	(5.5)	3.9	10.5	(13.0)	(20.5)	2.7	(10.7)	(19.3)	(34.5)	(33.2)	(23.7)	(28.6)	(34.1)
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax & Net
Income Tax Expense	3.9	1.0	1.2	0.3	0.5	-	-	-	-	-	-	-	-	-	-
Per Share
EPS Basic	0.19	(0.08)	0.04	0.12	(0.31)	(0.62)	(0.22)	(1.23)	-	-	-	-	-	-	-	-
Supplementary Data
EBITDA	-	(4.0)	5.2	11.7	(11.9)	(19.3)	4.0	(9.1)	(17.6)	(32.6)	(31.2)	(21.3)	(25.4)	(30.5)	(8.5)	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Income
Operating Income	21.1	(4.7)	2.1	1.2	(4.1)	7.2	4.0	(2.4)	(4.9)	(5.6)	(1.9)	20.4	(2.5)	(2.5)	(3.1)	(5.5)	(1.9)	(5.7)	(1.9)	(9.2)	(3.7)	2.8	(2.6)	(2.2)	4.7	2.2	(1.5)	(5.8)	(5.5)	(3.7)	(3.7)	(6.7)	(5.2)	(9.6)	(7.8)	(10.8)	(6.4)	(8.7)	(6.6)	(9.9)

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	(0.0)	(0.1)	0.1	(0.5)	0.4	0.1	(0.1)	0.2	0.1	(0.8)	0.2	(0.8)	(0.5)	(0.7)	(0.4)	0.2	(0.4)
Pre-Tax Income	21.1	(4.8)	2.2	0.7	(3.7)	7.3	3.8	(2.3)	(4.7)	(6.4)	(1.7)	19.6	(2.9)	(3.2)	(3.6)	(5.3)

Tax & Net
Income Tax Expense	2.8	0.7	(0.1)	0.5	(0.1)	0.8	0.6	(0.1)	(0.1)	(0.4)	0.1	0.3	0.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	18.3	(5.5)	2.4	0.2	(3.6)	6.5	3.2	(2.2)	(4.6)	(6.0)	(1.9)	19.3	(3.1)	(3.7)	(3.6)	(5.3)	(2.3)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	18.3	(5.5)	2.4	0.2	(3.6)	6.5	3.2	(2.2)	(4.6)	(6.0)	(1.9)	19.3	(3.1)	(3.7)	(3.6)	(5.3)	(2.3)
Net Income Attributable To Parent	18.3	(5.5)	2.4	0.2	(3.6)	6.5	3.2	(2.2)	(4.6)	(6.0)	(1.9)	19.3	(3.1)	(3.7)	(3.6)	(5.3)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	18.3	(5.5)	2.4	0.2	(3.6)	6.5	3.2	(2.2)	(4.6)	(6.0)	(1.9)	19.3	(3.1)	(3.7)	(3.6)

Per Share
EPS Basic	0.23	-	0.03	0.00	(0.05)	-	0.04	(0.03)	(0.06)	-	(0.03)	0.29	(0.05)	-	(0.07)	(0.11)	(0.05)	-	(0.09)	(0.25)	(0.14)	-	(0.14)	-	-	-	-	-	-	-	-	(0.06)	-	-	-	0.00	-	-	-	(0.11)
EPS Diluted	0.22	-	0.03	0.00	(0.05)	-	0.03	(0.03)	(0.06)	-	(0.04)	0.21	(0.05)	-	(0.07)	(0.11)	(0.05)	-
Shares Basic	79.8	-	79.3	78.7	76.6	-	73.5	73.3	73.0	-	72.3	67.2	57.5	-	49.5	47.3	45.8	-
Shares Diluted	83.0	-	80.8	81.3	76.6	-	81.2	73.3	73.0	-	83.8	83.2	57.5	-	49.5	47.3	45.8	-

Supplementary Data
EBITDA	21.6	-	-	-	(3.8)	-	-	-	(4.5)	-	-	-	(2.2)	-	-	-	(1.6)	-	-	-	(3.4)	-	-	-	5.1	-	-	-	(5.1)	-	-	-	(4.7)	-	-	-	(5.9)	-	-	-
EBIT	21.1	(4.7)	2.1	1.2	(4.1)	7.2	4.0	(2.4)	(4.9)	(5.6)	(1.9)	20.4	(2.5)	(2.5)	(3.1)	(5.5)	(1.9)	(5.7)	(1.9)

Operating Expenses
Research & Development	5.4	5.6	4.5	6.0	3.5	4.1	3.0	3.0	2.9	3.1	3.7	4.5	5.8	5.6	7.4	7.6	8.8	7.6	7.3	7.7	7.1	11.0	7.7	9.2	10.3	9.6	10.0	13.3	11.7	8.5	10.1	7.5	7.3	9.8	7.1	9.3	6.0	6.7	6.4	10.0
Selling General & Administrative	3.1	3.5	2.9	2.6	2.6	3.0	2.6	3.5	3.1	4.1	3.7	4.0	3.1	3.1	2.8	2.6
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	0.4	-	-	-	0.3	-	-	-	0.3	-	-	-	0.3	-	-	-
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-